Speakers:
– Alan Hennessy, Discovery & Exploratory Team Lead, GARDP (Switzerland)
– Mo Yin, Consultant, ADVANCE-ID, National University Hospital (Singapore)
– Herbert Wetli, Head of Pharmaceutical Development, GARDP (Switzerland)
Moderator:
Rosemary Dorrington, Professor of Microbiology, Rhodes University (South Africa)
A key measure to mitigate antimicrobial resistance is to develop new antibiotics but how is this done? Join us for an introduction to the stages of this process from discovery to clinical trials and pharmaceutical development. A must-watch for students and clinicians or anyone interested in learning more about what is being done to control the AMR crisis.
Presentation 1: An Overview of Modern Antibacterial Discovery (Alan Hennessy)
An overview of antibacterial discovery up to pre-clinical and filing an investigational new drug (IND) application
Examples of the discovery approach for recent products, clinical compounds, leads, hits etc.
Recent trends in antibacterial discovery
Presentation 2: An overview of antibiotic clinical trials (Mo Yin)
Introduction of Phase 1 to 3 randomised controlled trials
Real world examples of antibiotic clinical trials and their interpretation
Novel trial methodologies relevant to antibiotics
Presentation 3: Chemistry, Manufacturing and Controls (CMC) in Drug Development (Herbert Wetli)
Role of Chemistry, Manufacturing and Controls (CMC) throughout the development and commercialization of pharmaceutical products
CMC activities along the drug development path
CMC in late development and lifecycle management
This live webinar includes an interactive Q&A session.
Date and time:
19 September 2024 at 10:00 – 11:30 CEST
Dedicated registration link here
